{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:53:47Z","timestamp":1756461227520,"version":"3.44.0"},"reference-count":37,"publisher":"BMJ","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Antipsychotic drugs are licensed as treatment for schizophrenia and other mental health disorders but can cause a range of unwanted effects that require close monitoring by, and close collaboration between, healthcare professionals across a range of settings. This applies to both first-generation and second-generation antipsychotics (FGAs and SGAs; sometimes known as conventional and atypical antipsychotics, respectively). Here we discuss monitoring for unwanted effects of antipsychotics in adults, with a particular focus on SGAs.<\/jats:p>","DOI":"10.1136\/dtb.2011.02.0063","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T06:46:45Z","timestamp":1318402005000},"page":"117-120","source":"Crossref","is-referenced-by-count":9,"title":["Monitoring unwanted effects of antipsychotics"],"prefix":"10.1136","volume":"49","member":"239","published-online":{"date-parts":[[2011,10,12]]},"reference":[{"key":"2025082702202236000_49.10.117.1","unstructured":"Pharmaceutical Press, 2011. Martindale: the complete drug reference [online]. Available: http:\/\/www.medicinescomplete.com\/ [Accessed 31 August 2011]."},{"issue":"9","key":"2025082702202236000_49.10.117.2","first-page":"H1","article-title":"Atypical (second-generation) antipsychotics: reminder to monitor and manage weight, glucose, and lipid levels","volume":"4","author":"Medicines and Healthcare products Regulatory Agency and Commission on Human Medicines","year":"2011","journal-title":"Drug Safety Update"},{"key":"2025082702202236000_49.10.117.3","unstructured":"National Institute for Health and Clinical Excellence, 2009. Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Clinical guideline 82 [online]. Available: http:\/\/www.nice.org.uk\/nicemedia\/live\/11786\/43608\/43608.pdf [Accessed 22 September 2011]."},{"key":"2025082702202236000_49.10.117.4","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Second edition. Arlington, Va: APA, 2004."},{"key":"2025082702202236000_49.10.117.5","doi-asserted-by":"crossref","unstructured":"Tarsy D . Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. In: Weiner WJ Tolosa E (Eds). Handbook of clinical neurology. Boston: Elsevier BV, 2011.","DOI":"10.1016\/B978-0-444-52014-2.00043-4"},{"key":"2025082702202236000_49.10.117.6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.8.1334"},{"key":"2025082702202236000_49.10.117.7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Brit J Psych"},{"key":"2025082702202236000_49.10.117.8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2025082702202236000_49.10.117.9","doi-asserted-by":"crossref","unstructured":"Guy W . ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare, 1976.","DOI":"10.1037\/e591322011-001"},{"key":"2025082702202236000_49.10.117.10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.164.6.870"},{"key":"2025082702202236000_49.10.117.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806994"},{"key":"2025082702202236000_49.10.117.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2009.02.007"},{"key":"2025082702202236000_49.10.117.13","unstructured":"Haldol 5mg tablets. Summary of product characteristics, EU. Janssen-Cilag Ltd, February 2010."},{"key":"2025082702202236000_49.10.117.14","unstructured":"Orap 4mg tablets. Summary of product characteristics, EU. Janssen-Cilag Ltd, February 2010."},{"key":"2025082702202236000_49.10.117.15","doi-asserted-by":"crossref","unstructured":"Taylor D Paton C . The Maudsley Prescribing Guidelines. 10th edition., London: Informa Healthcare 2009.","DOI":"10.3109\/9780203092835"},{"key":"2025082702202236000_49.10.117.16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.5.607"},{"key":"2025082702202236000_49.10.117.17","unstructured":"Seroquel 25mg, 100mg, 150mg, 200mg and 300mg film-coated tablets. Summary of product characteristics, EU. Astra Zeneca UK Ltd, January 2010."},{"key":"2025082702202236000_49.10.117.18","unstructured":"Denzapine 25, 50, 100 and 200mg tablets. Summary of product characteristics, EU. Merz Pharma UK Ltd, June 2010."},{"key":"2025082702202236000_49.10.117.19","unstructured":"Risperdal Tablets, Liquid and Quicklet. Summary of product characteristics, EU. Janssen-Cilag Ltd, July 2010."},{"key":"2025082702202236000_49.10.117.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4245"},{"key":"2025082702202236000_49.10.117.21","unstructured":"Medicines and Healthcare products Regulatory Agency, 2009. The risk of thromboembolism associated with antipsychotics. MHRA Public Assessment Report [online]. Available: http:\/\/www.mhra.gov.uk\/home\/groups\/pl-p\/documents\/websiteresources\/con049075.pdf [Accessed 22 September 2011]."},{"issue":"8","key":"2025082702202236000_49.10.117.22","first-page":"5","article-title":"Antipsychotics: use in elderly people with dementia","volume":"2","author":"Medicines and Healthcare products Regulatory Agency, Commission on Human Medicines","year":"2009","journal-title":"Drug Safety Update"},{"key":"2025082702202236000_49.10.117.23","doi-asserted-by":"publisher","DOI":"10.2165\/11319120-000000000-00000"},{"key":"2025082702202236000_49.10.117.24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.08121844"},{"key":"2025082702202236000_49.10.117.25","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2007.10.0002"},{"key":"2025082702202236000_49.10.117.26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/070674370605100803","article-title":"The metabolic effects of antipsychotic medications","volume":"51","author":"Newcomer","year":"2006","journal-title":"Can J Psychiatry"},{"key":"2025082702202236000_49.10.117.27","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318166c4f7"},{"key":"2025082702202236000_49.10.117.28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J Psychopharmacol (Oxford)"},{"key":"2025082702202236000_49.10.117.29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881107087951","article-title":"Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists","volume":"22","author":"Holt","year":"2008","journal-title":"J Psychopharmacol (Oxford)"},{"key":"2025082702202236000_49.10.117.30","unstructured":"Solian. Summary of product characteristics, EU. Sanofi Aventis, February 2010."},{"key":"2025082702202236000_49.10.117.31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Peveler","year":"2008","journal-title":"J Psychopharmacol (Oxford)"},{"key":"2025082702202236000_49.10.117.32","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-7-201004060-00006"},{"key":"2025082702202236000_49.10.117.33","unstructured":"Zyprexa 2.5mg, 5mg, 7.5mg, 10mg, 15mg, and 20mg coated tablets. Zyprexa Velotab 5mg, 10mg, 15mg, and 20mg orodispersible tablets. Summary of product characteristics, EU. Eli Lilly and Company Limited, November 2010."},{"key":"2025082702202236000_49.10.117.34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J Psychopharmacol (Oxford)"},{"key":"2025082702202236000_49.10.117.35","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32819f8f17"},{"key":"2025082702202236000_49.10.117.36","doi-asserted-by":"crossref","unstructured":"Mitchell AJ . Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine 2011; doi:10.1017\/S003329171100105X.","DOI":"10.1017\/S003329171100105X"},{"key":"2025082702202236000_49.10.117.37","unstructured":"NHS Employers, 2011. Quality and outcomes framework guidance for GMS contract 2011\/12. Delivering investment in general practice [online]. Available: http:\/\/www.nhsemployers.org\/SiteCollectionDocuments\/QOFguidanceGMScontract_2011_12_FL%2013042011.pdf [Accessed 22 September 2011]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2011.02.0063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:20:33Z","timestamp":1756286433000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2011.02.0063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10,12]]},"published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1136\/dtb.2011.02.0063"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2011.02.0063","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}